Treatment of ABO hemolytic disease with synthetic blood group trisaccharides.
Thirteen infants, 10 with A-O and 3 with B-O hemolytic disease of the newborn (ABO-HDN), were treated with synthetic A or B blood group trisaccharides (ATS, BTS) which cause dissociation of maternal antibody bound to infant red cells. The clinical outcome was compared with that of a control group of 21 infants treated with phototherapy during the preceding year. Exchange transfusion was required in 2 out of 13 infants in the experimental group and in 7 in the control group. A randomized prospective controlled study is necessary to confirm these results.
Laboratory of Pathophysiology, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas, Venezuela.
E L
EL
Romano
A
A
Soyano
R F
RF
Montaño
M
M
Ratcliffe
M
M
Olson
G
G
Suarez
N
N
Martínez
G
G
Worsley
D000017:ABO Blood-Group System / Q000502:physiology*; D004899:Erythroblastosis, Fetal / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010789:Phototherapy; D012698:Serologic Tests; D014312:Trisaccharides / Q000097:blood / Q000627:therapeutic use*
D000017:ABO Blood-Group System; D014312:Trisaccharides